NCI Director Broder, Going On 3rd Year, Examines Issues Of Funding, Priorities, For Institute’s Future
In Brief: Tipping Resigns Forom ACS; Vaughan Joins UAB BMT Program; PCI Recruits Ball, Finn, Mirro
‘Be Careful We’re Not Fighting Old Battles’ On Study Section Issue
‘We Cannot Tolerate One Third Reduction In Centers. Prevention, Clinical Trials Programs’
“NIH Reveres, Honors, respects And Defends One And Only One Mechanisms’ – R01s
Centers Program Needs ‘Innovative Additions’ Such as SPORE Grants
Broder Not Satisfied With Mortality STATS On Three Major Cancers
Trending Stories
- Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Letai: MCEDs are a “great ideal”—alas, the data don’t support widespread use
“Projecting sub-ideal tests across a large population can cause harm,” Letai says, as Galleri cruises toward FDA approval - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”
- Cancer vaccine policy in limbo as CDC keeps canceling advisory meetings
